Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Binder

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
JCO Oncology Practice|April 15, 2025
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
American Journal of Hematology|June 26, 2026
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple MyelomaKenneth J C Lim, Shaji Kumar, Ricardo Parrondo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMMLChristopher T Letson, Maria E Balasis, Hannah Newman, et al.
American Journal of Hematology|January 11, 2022
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantationNadine H Abdallah, Thomas Habermann, Francis K Buadi, et al.
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|October 26, 2021
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformationXiaona You, Fabao Liu, Moritz Binder, et al.
Blood Cancer Journal|June 14, 2018
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaArjun Lakshman, S Vincent Rajkumar, Francis K Buadi, et al.
Blood Advances|April 10, 2026
Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucelKenneth Jc Lim, Hee Eun Lee, Zongming Eric Chen, et al.
JACC. Cardiooncology|April 22, 2026
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 PatientsEli Muchtar, Susan Geyer, Angela Dispenzieri, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Blood Cancer Journal|January 3, 2026
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
JCO Oncology Practice|April 15, 2025
Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
American Journal of Hematology|June 26, 2026
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple MyelomaKenneth J C Lim, Shaji Kumar, Ricardo Parrondo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMMLChristopher T Letson, Maria E Balasis, Hannah Newman, et al.
American Journal of Hematology|January 11, 2022
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantationNadine H Abdallah, Thomas Habermann, Francis K Buadi, et al.
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Blood|October 26, 2021
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformationXiaona You, Fabao Liu, Moritz Binder, et al.
Blood Cancer Journal|June 14, 2018
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaArjun Lakshman, S Vincent Rajkumar, Francis K Buadi, et al.
Blood Advances|April 10, 2026
Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucelKenneth Jc Lim, Hee Eun Lee, Zongming Eric Chen, et al.
JACC. Cardiooncology|April 22, 2026
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 PatientsEli Muchtar, Susan Geyer, Angela Dispenzieri, et al.
Pageof 10